![]() Forty-six of 157 (29.3%) patients had poor outcome (modified Ranking Scale score, ≥4), and hematoma expansion was observed in 29 of 144 (20.1%) patients. Cerebral microbleeds were present in 120 patients. Results A total of 167 patients were included their mean (SD) age was 61.9 (13.2) years, and 98 (58.7%) were male. The secondary outcome of interest was hematoma volume expansion of at least 33% on a CT scan obtained 24 hours after randomization compared with the entry scan. Main Outcomes and Measures The primary outcome of interest was death or disability (modified Ranking Scale score, 4-6) at 3 months. Eight hundred thirty-three participants were excluded, leaving 167 who had an interpretable axial T2*-weighted gradient-recalled echo sequence on magnetic resonance imaging to assess CMBs for inclusion in these subgroup analyses. Eligible participants were aged at least 18 years with ICH volumes less than 60 mL on computed tomography (CT) and a Glasgow Coma Scale score of at least 5 on initial assessment, in whom study drug could be initiated within 4.5 hours of symptom onset. Participants were enrolled between May 2011 and September 2015 and followed up for 3 months. Analyses followed the intent-to-treat paradigm. The ATACH-2 was an open-label international randomized clinical trial that investigated optimal acute BP lowering in 1000 patients with acute ICH. Objectives To characterize cerebral microbleeds (CMBs) in acute ICH and to assess the potential for interaction between underlying small vessel disease (as indicated by CMB number and location) and assignment to acute intensive BP targeting for functional outcomes and hematoma expansion.ĭesign, Setting, and Participants Preplanned subgroup analyses in the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) trial were performed. ![]() Importance Response to intensive blood pressure (BP) lowering in acute intracerebral hemorrhage (ICH) might vary with the degree of underlying cerebral small vessel disease. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.JR has an in-depth knowledge of his products, and is capable of solving problems of any level of complexity, and if necessary has the contacts to get any problem escalated. “JR provides something that is sadly rare these days - outstanding service! - JR is not only extremely knowledgeable about the products he sells & supports, but he also goes the extra mile to make sure everything is working well for you. As a Failure Analysis Engineer for the last 44 years, I will show you to prevent Crypto / Ransomware infection. Once ransomware occurs, protection has failed, and the customers hate you. I am a Crypto / Ransomware Prevention Specialist, and this is the worst possible, of all malware. I have done extensive research in this field for many years. I have made it my life's goal to prevent Organized Crime and Terrorists from using our own computers, against us, to fund the insurgents, who kill our own kids in war. Our company was started in 1966 in Tucson, Arizona, and we have supported anti-virus since its inception. Your Computer Is an Investment: Protect It With Avast Antivirus.Wherever You Purchased Your Notebook, Advantage Micro Corporation Can Provide Your Service And Support. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |